ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, announces that ...
Revolutionising healthcare with peptide-based therapies in specialist therapeutic areas
ImmuPharma PLC is an AIM listed (LSE:IMM) evolving speciality Bio-pharma company that discovers and develops peptide-based therapeutics. The Company is headquartered in London with its R&D team, ImmuPharma Biotech, based in France.
The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 is a first-in class immune “restorer” for the treatment of autoimmune diseases and is in Phase 3 for SLE (Lupuzor™ is the disease trademark).
Preclinical analysis suggests therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action, based on the P140 platform technology.
ImmuPharma and Avion Pharmaceuticals have an exclusive licence and development agreement and trademark agreement for Lupuzor™ to fund a new international Phase 3 study for Lupuzor™ and commercialise in the US.
4 core lead assets, 2 at late clinical stage
Lupuzor™
Autoimmunity
Lupus
Status
Phase 3 study (pivotal)
Study start
2023/24
P140
Inflammation
CIDP
Status
Phase 2/3 adapative (pivotal)
Study start
2023/24
BioAMB
Anti-infection
Severe Fungal infection
Status
Late pre-clinical
Partnering
2023/24
BioCIN
Anti-infection
Severe Bacterial infection
Status
Late pre-clinical
Partnering
2023/24
Why Invest in ImmuPharma?
- A rich portfolio with 2 highly attractive late-stage clinical indications – SLE & CIDP
- Near-term business development opportunities across all programs
- Innovative P140 Bio-drug platform has the potential in several autoimmune diseases and life cycle management through it’s second generation P140
Key progress
Financial, Business and Portfolio Development Update
ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, is pleased ...
Simbec-Orion appointed as CRO | Decision to move directly into a Phase 3 pivotal study | Compelling findings on P140’s MOA
ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, is pleased ...
Market Cap
15 minute delayed share price provided by Hemscott Group Limited Disclaimer
Share Price - more details
Market Commentary
Professional advisers
Nominated Adviser ‘NOMAD’
SPARK Advisory Partners Limited
www.sparkadvisorypartners.com
Joint Broker
Stanford Capital Partners Limited
5-7 Cranwood Street
London
EC1V 9EE
www.stanfordcp.co.uk/contact-us
Joint Broker
Si Capital Limited
info@sicapital.co.uk
Public Relations & Investor Relations
lisa.baderoon@immupharma.com
Auditors
Evelyn Partners, 45 Gresham St,
London EC2V 7BG
Legal Representatives
BDB Pitmans LLP
London, U.K.
Badertscher Rechtsanwälte AG
Zurich, Switzerland
Patent Agents
Cantor Colburn, LLP, USA
Haseltine Lake Kempner LLP, UK
Manufacturers
Polypeptide
Bachem (Bioglucagon)
BCN